Parts of East Asia have a very high upper tract urothelial carcinoma (UTUC) prevalence, and an 25 etiological link between the medicinal use of herbs containing aristolochic acid (AA) and UTUC 26 has been established. The mutational signature of AA, which is characterized by a particular 27 pattern of A:T to T:A transversions, can be detected by genome sequencing. Thus, integrating 28 mutational signatures analysis with clinicopathological data may be a crucial step toward 29 personalized treatment strategies for the disease. Therefore, we performed whole-genome 30 sequencing (WGS) of 90 UTUC patients from China. Mutational signature analysis via 31 nonnegative matrix factorization method defined three etiologically distinct subtypes with 32 prognostic relevance: (i) AA, the typical AA mutational signature characterized by signature 22, 33 had the highest tumor mutation burden, the best clinical outcomes; (ii) Age, an age-related group 34 featured by signatures 1 and 5, had the lowest weighted genome instability index score, the worst 35 clinical outcomes; and (iii) DSB, signature with deficiencies in DNA double strand break-repair 36 featured by signatures 3, the intermediate clinical outcomes. Additionally, the distinct AA subtype 37
Abstract 24 Parts of East Asia have a very high upper tract urothelial carcinoma (UTUC) prevalence, and an 25 etiological link between the medicinal use of herbs containing aristolochic acid (AA) and UTUC 26 has been established. The mutational signature of AA, which is characterized by a particular 27 pattern of A:T to T:A transversions, can be detected by genome sequencing. Thus, integrating 28 mutational signatures analysis with clinicopathological data may be a crucial step toward 29 personalized treatment strategies for the disease. Therefore, we performed whole-genome 30 sequencing (WGS) of 90 UTUC patients from China. Mutational signature analysis via 31 nonnegative matrix factorization method defined three etiologically distinct subtypes with 32 prognostic relevance: (i) AA, the typical AA mutational signature characterized by signature 22, 33 had the highest tumor mutation burden, the best clinical outcomes; (ii) Age, an age-related group 34 featured by signatures 1 and 5, had the lowest weighted genome instability index score, the worst 35 clinical outcomes; and (iii) DSB, signature with deficiencies in DNA double strand break-repair 36 featured by signatures 3, the intermediate clinical outcomes. Additionally, the distinct AA subtype 37 was associated with AA exposure, the highest number of predicted neoantigens and heavier 38 lymphocytes infiltrating. Thus, it may be good candidate for immune checkpoint blockade therapy. 39 Notably, we showed AA-mutational signature was also identified in histologically "normal" 40 urothelial cells. Thus, non-invasive urine test based on the AA-mutational signature could take 41 advantage of this "field effect" to screen individuals at increased risk of recurrence due to exposure Introduction 47 The epidemiology and clinicopathological characteristics of UTUC is largely influenced by its 48 geographic distribution. Parts of East Asia such as Taiwan have a much higher UTUC prevalence, 49 accounting for more than 30% of urothelial cancers (UCs)(1-3) compared to only 5-10% of UCs 50 in Western populations(4). Chinese patients are more frequently female, of higher rate for kidney 51 failure(5). Conceivably, geographic differences in risk factors for UTUC, such as AA-containing 52 herb drugs consumption may account for some of these observations (1, (6) (7) (8) . It has been shown 53 that AA-induced mutational signature was characterized by A:T to T:A transversions at the 54 sequence motif A[C|T]AGG (8, 9) . The unusual genome-wide AA signature, termed signature 55 22 in COSMIC, holds great potential as "molecular fingerprints" for AA exposure in multiple 56 cancer types (7, 9) . Similarly, other endogenous or exogenous DNA damaging agents will also 57 create mutational signatures detectable by DNA sequencing (10) The increased mutation load was consistent with the increased prevalence of exposure to the potent 78 mutagen AAs ( fig. 1B ). Next, we examined the candidate driver genes with MutSigCV (Q<0.05). 79 Only two genes, TP53 and FRG2C, were identified ( fig. 1C ). However, many genes listed in the 80 Cancer Gene Census as known driver genes were affected by non-silent mutations including genes 81 which frequently mutated in Western UTUC patients, such as KMT2D (18%) and ARID1A (14%) 82 ( fig. 1C ). Additionally, the overall genomic landscape confirmed the dominance of recurrent 83 CNVs compared with SNVs and indels in the cohort ( fig. 1D ).
84
Mutational signatures define three UTUC subtypes with distinct etiology 85 Next, we explored the dynamic interplay of risk factors and cellular processes using mutational 86 signature analysis. We identified 23 mutational signatures defined by COSMIC in our cohort, improved prognostic stratification could offer more tailored therapeutic decisions, we further 113 stratified the patients into subgroups, muscle invasion and non-muscle invasion subgroups. 114 Consistently, the AA and DSB subtypes also exhibited favourable outcomes in muscle-invasive 115 6 UTUC patients (log-rank, p=0.001 for CSS, log-rank, p=0.002 for MFS) ( fig. 3C and 3D). In 116 multivariate Cox regression proportional analyses adjusted for the effects of standard 117 clinicopathologic variables, mutational subtypes were still an independent risk factor for CSS 118 (Hazard Ratio [HR]=4.05, 95% CI: 1.58~10.42, p=0.004) and MFS (HR=3.43, 95% CI: 1.46~8.06, 119 p=0.006) (table S3) . We also used the recently described mutational signature deconvolution 120 method, Mutalisk, for comparison(23). This method was based on different statistical frameworks, 121 and therefore some differences were to be expected. Nevertheless, we observed the same key Integration of mutational signature subtypes with copy number alterations 130 One practical question was how this subtyping could be implemented clinically. Previous study 131 had showed that 10X coverage data can confidently retrieve dominant signatures(11). Therefore, 132 lower-coverage WGS could provide a cost-effective alternative for signature-based stratification 133 especially for the AA subtype (more than 35% mutations contributed by signature 22 in our cohort). 134 Although for the Age and DSB subtype which did not have the dominant signatures, we next 135 explored whether CNV features can distinguish these two subtypes. First, we examined the 136 landscape of CNVs in UTUC by ichorCNA(24) which can predict CNVs in tumor-only samples. (26), which is the development of a field with genetically altered cells, has been 156 proposed to explain the development of multiple primary tumours and local recurrence. Therefore, 157 we further sequenced three AA subtype patients (table S4) (table S6) . We found the number of CD3 + lymphocytes was positively associated with the number 180 of stromal TIMCs (R 2 =0.72; p<0.001) (fig. 5B ). The AA subtype had the highest number of both 181 stromal TIMCs (Wilcoxon rank test, p<0.001) and CD3 + lymphocytes (Wilcoxon rank, p<0.001) 182 ( fig. 5C and 5D ). Representative images from a patient of the AA subtype and the Age subtype 183 were shown in the fig. 5E and fig. 5F derivatives may still be widespread in China. Notably, we showed AA-mutational signature was 199 also identified in histologically "normal" urothelial cells. In a published study(34), similar "field 200 effect" was also identified in an Chinese UTUC patient. Thus, non-invasive urine test based on the 201 AA-mutational signature could take advantage of this "field effect" to screen individuals at 202 increased risk of recurrence due to exposing to herbal remedies containing the carcinogen AA. 203 One limitation of current study was lack of a matched normal for 85 of 90 UTUC patients due 204 to lack of funds. Therefore, we relied on the public mutation database and in-house genomic data 205 of 1000 healthy Chinese individuals for the filtering germline variances. But in recent years, these 206 catalogs of human variation have grown exponentially, questioning the necessity of sequencing a 207 matched normal for every tumor sample(35). Additionally, a matched normal will not be available 208 in many pathological conditions, such as cancer cell lines and liquid biopsy. Although we can not 209 make definite conclusions that the SNVs identified in current study were somatic mutations. We 210 may also overcall the Age subtypes without a matched normal since germline variants contributed 211 to signature 5 in COSMIC which combined with signature 1 as age-related signature in current 212 study. However, with this caveat, the mutational signature subtypes did capture distinct clinical 213 and genomic features, such as better overall survival, higher level of wGII and higher level of MSI 214 in DSB subtype compared to Age subtype of patients. 215 Additionally, our study supports a rationale for management of UTUC, most notably the AA 216 subtype. Patients with AA mutational signature may predict better checkpoint inhibitors response. 217 Strikingly, the DSB subtype was featured by signature 3 in COSMIC. In pancreatic cancer, 218 responders to platinum therapy usually exhibit signature 3 mutations(36). These results suggested 219 that platinum-based therapy may also benefit UTUC patients of DSB subtype. More recently, 220 protein components of the DNA damage repair (DDR) systems have been identified as promising 221 avenues for targeted cancer therapeutics(37). We also further assessed the mutation rates across 222 345 genes associated with DDR, as previously described in a pan-cancer analysis(37) ( fig. S7) . 223 There was a 1.6 fold enrichment (P=0.007, 95% CI: (17) was carried out to assign each sample' signature. We discovered 267 23 COSMIC signatures which were merged by shared etiologies into 9 signatures in our cohort. 268 We named signature 22 which has been found in cancer samples with known exposures to 269 aristolochic acid(1, 8) as AA, DNA double strand break-repair deficiency featured by signature 3 270 as DSB. We merged signature 1 and 5 as Age (18) 277 To determine copy number states, we used a recently published method(44). Briefly, the genome 278 was divided into bins of variable length with an equal amount of potential uniquely mapping reads. 279 We simulated approximately 37X hg19 reads mapped by BWA and divided the genome into 280 50,000 bins of the same mapping ability. Loess normalization was used to correct for GC bias. as covariates. We applied the cut off 0.05 for Q value. Cancer census genes from COSMIC(48) 286 release v87 were calculated for their mutation rates (mutations/gene length) and genes with more 287 than 10 samples were selected with high mutation rates.
Copy number variations (CNVs) analysis

288
The weighted genome integrity index score (wGII) analysis 289 We calculated the wGII score as reported (49) for the absence of MSI signature (signature 6, 15, 20, 21, 26, 27) as defined by COSMIC(48).
298
Neoantigen prediction 299 HLAscan(53) was used to genotype the HLA region with HLA-A, HLA-B and HLA-C taken into 300 consideration. NetMHC4.0(54) was used for predictions of peptide-MHC class I interaction, SNVs 301 annotated by Annovar(43) as nonsynonymous were used to do this analysis. An in-house script 302 was carried out to obtain possible 9-amino acid sequences covering the mutated amino acids 303 according to the manual. Rank in the output that was no more than two were considered as binding 304 in the light of BindLevel suggestion.
305
Assessing tumor-infiltrating lymphocytes 306 The tumor infiltrating mononuclear lymphocytes were measured according to a standardized 307 method from the International Immuno-Oncology Biomarkers Working Group(55). And the CD3 308 antibody (ab5690, 1:10000; Abcam) was used to evaluate the CD3 + lymphocytes in tumor section. 
